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ABSTRACT 
Objective: Development of a simple, selective, precise, high-performance thin layer chromatographic method for the analysis of carbocisteine, 
mucolytic drug in pharmaceutical dosage form.  
Methods: The proposed HPTLC method employed TLC aluminum plates precoated with silica gel 60F-254 as the stationary phase. The solvent system 
consisted of butanol: water: ethanol: acetic acid (5:1.5:2:1.5 v/v/v/v). This system was found to give compact spots for carbocisteine with Rf value of 0.34. 
Results: The reported method is linear over the range of 50-800 ng/spot with a coefficient of correlation 0.9992. The precision study revealed that 
the percentage relative standard deviation was within the acceptable limit. The developed method was validated according to ICH Guidelines.  
Conclusion: An economical, accurate, sensitive and precise HPTLC method was developed and fully validated for quality control analysis of 
carbocisteine in tablets. The developed method was validated with respect to specificity, limit of detection, limit of quantification, precision, 
linearity, accuracy and robustness. Validation results were found to be satisfactory. The proposed method can be used for routine analysis of 
carbocisteine in quality control laboratories. 
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Carbocisteine is a mucolytic agent, chemically is (R)-2-Amino-3-
(carboxymethyl sulfanyl) propanoic acid with molecular formula 
C5H9NO4S and molecular weight of 179.2 9 [ fig. 1] used in 
respiratory disorders associated with a productive cough that 
reduces the viscosity of sputum and so can be used to help relieve 
the symptoms of the chronic obstructive pulmonary disorder 
(COPD) and bronchiectasis. In addition to its much regulatory 
activity, carbocisteine exhibits free-radical scavenging and anti-
inflammatory properties. These characteristics have stimulated 
interest in the potential that this and other mucoactive drugs may 
offer for modification of the disease processes present in COPD [1].  
 
 
Fig. 1: Chemical structure of carbocisteine 
 
Literature survey reveals that few methods have been reported for 
analysis of carbocisteine in plasma and bulk drugs which includes 
fluorimetric method [2], spectrophotometric method [3] and high-
performance liquid chromatography (HPLC) [4-12]. 
There was no HPTLC method for estimation of carbocisteine has 
been reported so far. Hence an attempt has been made to develop a 
new precise and accurate HPTLC method for estimation of 
carbocisteine in the formulation as per ICH guidelines [13]. The 
advantage of HPTLC is that several samples can be run 
simultaneously by using a small quantity of mobile phase unlike 
HPLC, thus lowering analysis time and cost per analysis.  
MATERIALS AND METHODS 
Chemicals and reagents 
Carbocisteine pure compound was purchased from swapnaroop 
drugs and chemicals, Aurangabad. Carbocisteine capsules, 
mucodyne was purchased from a local pharmacy. All the chemicals 
used were of analytical grade.  
HPTLC instrumentation and chromatographic conditions 
The Samples were spotted in the form of bands of width 5 mm with 
a camag microlitre syringe on precoated silica gel aluminum plate 
60F-254 (20 cm x 10 cm) with 250 µm thickness; Merck, Germany) 
using a Camag Linomat IV applicator (Switzerland). A constant 
applications rate 5 µl was employed and space between two bands 
was 5 mm. The slit dimension was kept at 4 mm x 0.5 mm and 20 
mm scanning speed was employed.  
The Mobile phase consisted of n-butanol: water: ethanol: acetic acid 
(5:1.5:2:1.5 v/v/v/v). Linear ascending development was carried out 
in twin trough glass chamber saturated with the mobile phase. The 
optimized chamber saturation time for mobile phase was 30 min. with 
filter paper at room temperature. The length of the chromatogram run 
was 9 cm. subsequent to the development. TLC plates were dried in air 
with the help of an air-dryer. Ninhydrin was used as the derivatizing 
reagent to improve chromatographic retention. Densitometric 
scanning was performed on Camag TLC scanner III in the absorbance 
mode at 366 nm and operated by CATS software (V 4.06, Camag). The 
Source of radiation utilized was deuterium lamp. 
Preparation of stock and standard solutions 
A stock solution of carbocisteine (1 mg/ml) was prepared by 
accurately weighing approximately 10 mg of carbocisteine into 10 
ml volumetric flask and volume was made up to the mark with 0.1N 
HCL. The standard solutions were prepared by dilution of the stock 
solution with 0.1N HCL to reach a concentration range 50-800 ng/µl. 
Each concentration was spotted six times on the TLC plate. The plate 
was developed on previously described mobile phase. The peak 
areas were plotted against the corresponding concentrations to 
obtain the calibration graphs. 
Preparation of sample solution 
For analysis of marketed formulation, twenty capsules were accurately 
weighed and the average weight was determined. Powder equivalent 
to 100 mg of carbocisteine was weighed, transferred to 100 ml of the 
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volumetric flask containing 0.1N HCL, sonicated for 15 min and diluted 
up to the mark with 0.1N HCL. The resulting solution was filtered 
through whatman filter paper and used for further analysis. 
Validation  
Validation of method was carried as per the International 
Conference on Harmonization [(ICH) Q2 (Rl)] guidelines for 
selectivity, robustness, linearity, range, limit of detection (LOD) and 
limit of quantitation (LOQ), accuracy, and precision [13]. 
Linearity and range 
Stock solutions were applied on the HPTLC plate in the range of 50-800 
ng/spot of carbocisteine to evaluate linearity. Peak area versus 
concentration was plotted and linear regression analysis and the 
correlation coefficient, slope, intercept for the calibration was estimated.  
LOD and LOQ 
Limit of detection and limit of quantitation was estimated using 
formula 3.3 σ/S and 10 σ/S, respectively, where σ is the standard 
deviation of the response (y-intercept) and S is the slope of the 
linearity plot. 
Precision studies 
Precision was studied by intra and inter-day precision. Carbocisteine 
sample was prepared and analyzed six times on the same day in 
order to trace any variations in the results. For interday variation 
study, the above-mentioned drug samples were analyzed on three 
successive days. 
Accuracy studies 
The accuracy of the method was determined by estimating 
recoveries of carbocisteine by the standard addition method. The 
sample was spiked with 80, 100 and 120 % of standard solutions.  
Robustness studies 
In the robustness evaluation, small, deliberate changes in the 
analytical parameters of the proposed method were done and its 
effect on the peak areas of the drugs was studied.  
Assay 
The proposed method was applied to the determination of 
carbocisteine in mucodyne capsules. To determine the content of 
carbocisteine in capsules (label claim: 375 mg carbocisteine) 20 
capsules were opened and the contents were weighed and mixed. An 
aliquot of powder equivalent to the weight of 1 mg was accurately 
weighed and transferred to 100 ml volumetric flask and was 
dissolved in 0.1N HCL and made up to the volume of 0.1N HCL. The 
volumetric flask was sonicated for 30 min to affect complete 
dissolution. The solutions were filtered through a 0.45 µm nylon 
filter. The above stock solution was further diluted to obtain sample 
solution at three different concentration levels of 200, 400 and 600 
ng/µl respectively was applied six times to the HPTLC plate. The 
plate was developed in the previously described chromatographic 
conditions.  
RESULTS AND DISCUSSION 
HPTLC method development and optimization 
The different solvent system was tried to optimize the method. 
Finally, a mobile phase consisting of butanol: water: ethanol: acetic 
acid (5:1.5:2:1.5 v/v/v/v) was optimized. To improve the resolution 
and to enhance the selectivity of carbocisteine, derivatization 
method has been developed for optimal and reproducible assay 
performances. Ninhydrin was used as the derivatizing reagent, and 
good resolution with Rf value of 0.34 for carbocisteine was obtained 
after derivatization when densitometric scanning was performed at 
366 nm. The spot appeared more compact and peak shape more 
symmetrical. The significantly improved chromatographic retention, 
and the highly selective and sensitive detection afforded by the 
HPTLC monitoring have made the method most useful for 
identification of carbocisteine in pharmaceutical dosage form. The 
typical chromatogram of carbocisteine was shown in [fig. 2]. 
 
Fig. 2: Chromatogram obtained from standard solution of 
carbocisteine 200 ng/spot 
 
Validation of method  
The method was validated with respect to parameters including 
linearity, limit detection (LOD), limit of quantitation (LOQ), 
recovery, precision, accuracy, robustness and selectivity. 
Linearity 
Linearity was established by least squares linear regression analysis 
of the calibration curve. The constructed calibration curves were 
linear over the concentration range of 50-800 ng per spot for 
carbocisteine [fig. 3]. Linear regression for carbocisteine was found 
to be r2 = 0.9992±0.034 [table 1].  
 
 
Fig. 3: Calibration curve for carbocisteine by HPTLC 
 
LOD and LOQ 
The LOD and LOQ were determined based on signal-to-noise ratios 
and were based on analytical responses of 3 and 10 times the 
background noise, respectively. The LOD and LOQ were found to be 
30.191 ng/spot and 91.697 ng/spot respectively for carbocisteine. 
 
Table 1: Statistical evaluation of calibration data 
Parameter  HPTLC 
Linearity Range ng/spot 50-800  
r2±%RSD  0.9992±0.034 
Slope±%RSD  7.9758±1.12 
Intercept±%RSD  134.02±0.86 
LOD (ng spot/spot) 30.191  
LOQ (ng spot/spot) 91.697 




Set of three different concentrations in three replicates of 200, 400 
and 600 (ng/µl) were prepared. All the solutions were analyzed on 
the same day in order to record intra-day variations in the results. 
Inter-day precision study involves analysis of three different 
concentrations of the standard solutions in linearity range on three 
consecutive days. Precision data is summarized in table 2. 
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Table 2: Intra and inter-day precision results of carbocisteine 
Concentration (ng/spot) Intra-day(n=6) %R.S.D* Inter-day(n=6) %R.S.D* 
200 100.8±0.54 99.67±0.83 
400 99.28±0.84 101.5±0.56 
600 99.14±0.96 98.86±1.26 
 n = Number of determinations, *Average of six determinants. 
 
Recovery 
The proposed method was used for estimation of carbocisteine from 
the pharmaceutical dosage form after spiking with an additional 
drug. The afforded recovery was found to be 98.84-101.06 % for 
carbocisteine from the marketed formulation [table 3]. 
Robustness of the method 
To evaluate HPTLC method robustness, a few parameters were 
deliberately varied. Results indicate that the selected factors 
remained unaffected by small variations of these parameters. The 
standard deviation of peak areas was calculated for each parameter 
and % RSD was found to be less than 2 %. The low values of % RSD 
indicated the robustness of the method [table 4]. 
Selectivity/specificity 
The peak purity of carbocisteine was assessed by comparing their 
respective spectra at peak start, peak apex and peak end positions of 
the spot, i.e., r (start, middle) = 0.9991 and r (middle, end) = 0.9995. 
A good correlation (r = 0.9993) was also obtained between standard 
and sample spectra of carbocisteine. 
 
Table 3: Recovery studies (n=6) results of carbocisteine 
Concentration (ng/spot) Amount of drug added (ng/spot) % Recovery±S. D* 
200  160  98.84±0.84  
200 400 99.29±0.16  
200 440 101.06±0.28  
mean±SD  99.73±0.42 
 *Average of six determinants, n = Number of determinations 
 
Table 4: Robustness evaluation of carbocisteine for HPTLC method 
Parameter SD of peak area  %RSD* 
Mobile phase composition (±0.1 ml) 0.82 0.32 
Amount of mobile phase (±5 %) 1.03 1.12 
Temperature (±2 %) 1.06 0.96 
Relative humidity (±5 %) 1.75 1.36 
Chamber Saturation (±5 min) 0.83 0.72 
Time from spotting to chromatography (±20 min) 0.62 0.24 
Time from chromatography to scanning (±5 min) 0.81 0.52 
 *Average of three determinants, SD-standard deviation, and RSD-Relative standard deviation 
 
Assay 
The drug content was found to be 100.07 %±1.57 for carbocisteine. 
It may, therefore, be inferred that degradation of carbocisteine had 
not occurred in the marketed formulations that were analyzed by 
the proposed method, and the low % RSD value indicated the 
suitability of this method for routine analysis of carbocisteine in 
pharmaceutical dosage form. 
CONCLUSION 
There was no HPTLC method for estimation of carbocisteine has 
been reported so far. Hence a new precise and accurate HPTLC 
method consisting butanol: water: ethanol: acetic acid (5:1.5:2:1.5 
v/v/v/v) as mobile phase was optimized. Ninhydrin was used as 
the derivatizing reagent and good resolution with Rf value of 0.34 
for carbocisteine was obtained at 366 nm. The drug shows 
linearity over the concentration range of 50-800 ng per spot and 
linear regression for carbocisteine was found to be r2 = 
0.9992±0.034. The developed method was validated as per ICH 
guidelines. The standard deviation and % RSD calculated for the 
proposed methods are subtle, indicating a high degree of precision 
of the methods. The results of the recovery studies performed to 
show the high degree of accuracy of the proposed methods. All the 
parameters like precision, accuracy, specificity, ruggedness, 
robustness were done and found to be within the acceptance 
criteria. From the experimental data, it can be concluded that the 
developed chromatographic method is accurate, precise and 
selective and can be employed successfully for the estimation of 
carbocisteine in pharmaceutical dosage form. 
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